A phase 1 double-blind, placebo controlled, dose-escalation, multi-center therapeutic trial of the safety, immunogenicity, and efficacy of GI-5005; an inactivated recombinant saccharomyces cerevisiae expressing a hepatitis C virus NS3-core fusion protein, in patients with chronic hepatitis C infection

Trial Profile

A phase 1 double-blind, placebo controlled, dose-escalation, multi-center therapeutic trial of the safety, immunogenicity, and efficacy of GI-5005; an inactivated recombinant saccharomyces cerevisiae expressing a hepatitis C virus NS3-core fusion protein, in patients with chronic hepatitis C infection

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2010

At a glance

  • Drugs GI 5005 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 11 May 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
    • 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Aug 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top